SOUTH SAN FRANCISCO, Calif., Oct. 16, 2022 (GLOBE NEWSWIRE) -- NGM Biopharmaceuticals, Inc. (NGM Bio) (Nasdaq: NGM) will host a conference call and live webcast on Monday, October 17, 2022 at 8:00 a.m. ET (5:00 a.m. PT) to discuss topline efficacy and safety results from its CATALINA Phase 2 trial of NGM621 in patients with geographic atrophy secondary to age-related macular degeneration.